Label Changes for:

Avastin (bevacizumab) Solution for intravenous infusion

December 2011

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011 

 

 

ADVERSE REACTIONS

Postmarketing Experience
  • include additional information regarding ocular and systemic adverse events following unapproved intravitreal use for treatment of various ocular disorders.
Hide
(web2)